首页> 美国卫生研究院文献>Annals of Cardiothoracic Surgery >8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice
【2h】

8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice

机译:食管和食管胃交界处癌症的第8版AJCC / UICC分期:在临床实践中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The 8th edition of the American Joint Committee on Cancer (AJCC) staging of epithelial cancers of the esophagus and esophagogastric junction (EGJ) presents separate classifications for clinical (cTNM), pathologic (pTNM), and postneoadjuvant (ypTNM) stage groups. Histopathologic cell type markedly affects survival of clinically and pathologically staged patients, requiring separate groupings for each cell type, but ypTNM groupings are identical for both cell types. Clinical categories, typically obtained by imaging with minimal histologic information, are limited by resolution of each method. Strengths and shortcomings of clinical staging methods should be recognized. Complementary cytology or histopathology findings may augment imaging and aid initial treatment decision-making. However, prognostication using clinical stage groups remains coarse and inaccurate compared with pTNM. Pathologic staging is losing its relevance for advanced-stage cancer as neoadjuvant therapy replaces esophagectomy alone. However, it remains relevant for early-stage cancers and as a staging and survival reference point. Although pathologic stage could facilitate decision-making, its use to direct postoperative adjuvant therapy awaits more effective treatment. Prognostication using pathologic stage groups is the most refined of all classifications. Postneoadjuvant staging (ypTNM) is introduced by the AJCC but not adopted by the Union for International Cancer Control (UICC). Drivers of this addition include absence of equivalent pathologic (pTNM) categories for categories peculiar to the postneoadjuvant state (ypT0N0-3M0 and ypTisN0-3M0), dissimilar stage group compositions, and markedly different survival profiles. Thus, prognostication is specific for patients undergoing neoadjuvant therapy. The role of ypTNM classification in additional treatment decision-making is currently limited. Precision cancer care advances are necessary for this information to be clinically useful.
机译:美国癌症联合委员会(AJCC)第8版对食管和食管胃交界处(EGJ)的上皮性癌症进行了分类(cTNM),病理学(pTNM)和新辅助后(ypTNM)分期。组织病理学细胞类型显着影响临床和病理分期患者的生存,每种细胞类型需要单独的分组,但是两种细胞类型的ypTNM分组是相同的。通常通过以最少的组织学信息成像获得的临床类别受每种方法分辨率的限制。应认识到临床分期方法的优缺点。补充细胞学或组织病理学发现可增强影像学,并有助于初始治疗决策。但是,与pTNM相比,使用临床分期的预后仍然很粗糙且不准确。由于新辅助疗法替代了单独的食管切除术,病理分期正在失去与晚期癌症的相关性。但是,它仍然与早期癌症以及作为分期和生存参考点有关。尽管病理分期可以促进决策,但将其用于指导术后辅助治疗尚待更有效的治疗。使用病理分期的预后是所有分类中最完善的。 AJCC引入了新辅助后分期(ypTNM),但国际癌症控制联盟(UICC)并未采用。这种增加的驱动因素包括缺乏新辅助后状态特有的类别(ypT0N0-3M0和ypTisN0-3M0)的等效病理(pTNM)类别,不同的阶段组组成以及明显不同的生存状况。因此,预后对于接受新辅助治疗的患者是特定的。 ypTNM分类在其他治疗决策中的作用目前受到限制。要使此信息在临床上有用,必须进行精确的癌症护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号